MX369030B - Sistemas transdérmicos restrictivos de abuso y mal uso. - Google Patents

Sistemas transdérmicos restrictivos de abuso y mal uso.

Info

Publication number
MX369030B
MX369030B MX2016009493A MX2016009493A MX369030B MX 369030 B MX369030 B MX 369030B MX 2016009493 A MX2016009493 A MX 2016009493A MX 2016009493 A MX2016009493 A MX 2016009493A MX 369030 B MX369030 B MX 369030B
Authority
MX
Mexico
Prior art keywords
abuse
misuse
deterrent
patch
aversive
Prior art date
Application number
MX2016009493A
Other languages
English (en)
Other versions
MX2016009493A (es
Inventor
James Enscore David
Tagliaferri Frank
Paul DAMON Steven
Smith Alan
C Gaulding Jeffrey
Original Assignee
4P Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4P Therapeutics filed Critical 4P Therapeutics
Publication of MX2016009493A publication Critical patent/MX2016009493A/es
Publication of MX369030B publication Critical patent/MX369030B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F214/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen
    • C08F214/18—Monomers containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F214/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen
    • C08F214/18—Monomers containing fluorine
    • C08F214/26—Tetrafluoroethene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un parche transdérmico restrictivo de abuso y restrictivo de mal uso que comprende agentes aversivos incorporados en la capa de soporte del parche. Los agentes aversivos pueden mostrar cinética bifásica o sostenida de liberación con una porción inmediata liberada rápidamente y una porción prolongada liberada en una manera prolongada cuando se expone a un medio de disolución. La liberación prolongada del agente aversivo proporciona la restricción contra la extracción del fármaco de parches recientes y usados y sirve para impedir el mal uso accidental de los parches usados por los niños. Los sistemas de parches restrictivos de abuso y restrictivos de mal uso se pueden usar para suministro transdérmico de agentes terapéuticamente activos y particularmente aquellos fármacos que son sumamente propensos al abuso tal como opioides y analgésicos opiáceos y estimulantes.
MX2016009493A 2014-01-22 2015-01-21 Sistemas transdérmicos restrictivos de abuso y mal uso. MX369030B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461930104P 2014-01-22 2014-01-22
US201461930090P 2014-01-22 2014-01-22
US201462014721P 2014-06-20 2014-06-20
US201462014723P 2014-06-20 2014-06-20
US201462083620P 2014-11-24 2014-11-24
PCT/US2015/012196 WO2015112563A2 (en) 2014-01-22 2015-01-21 Abuse and misuse deterrent transdermal systems

Publications (2)

Publication Number Publication Date
MX2016009493A MX2016009493A (es) 2017-05-09
MX369030B true MX369030B (es) 2019-10-25

Family

ID=53682116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009493A MX369030B (es) 2014-01-22 2015-01-21 Sistemas transdérmicos restrictivos de abuso y mal uso.

Country Status (20)

Country Link
US (5) US20170007550A1 (es)
EP (1) EP3096746B1 (es)
JP (1) JP6525165B2 (es)
KR (1) KR102226652B1 (es)
CN (3) CN115444659A (es)
AU (1) AU2015209466B2 (es)
CA (1) CA2937649C (es)
CY (1) CY1121654T1 (es)
DK (1) DK3096746T3 (es)
ES (1) ES2729871T3 (es)
HR (1) HRP20191048T1 (es)
HU (1) HUE044966T2 (es)
LT (1) LT3096746T (es)
MX (1) MX369030B (es)
PL (1) PL3096746T3 (es)
PT (1) PT3096746T (es)
RS (1) RS58759B1 (es)
RU (1) RU2700926C2 (es)
SI (1) SI3096746T1 (es)
WO (1) WO2015112563A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3096746T3 (da) 2014-01-22 2019-05-20 4P Therapeutics Transdermale systemer til forhindring af misbrug eller forhindring af fejlanvendelse
EP3250258A4 (en) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
CN108883078B (zh) * 2016-03-24 2022-09-09 美德阿利克斯株式会社 具有防止误用特性的贴剂
US20170273974A1 (en) 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
KR20210096592A (ko) * 2018-08-23 2021-08-05 번스타인, 에릭, 에프 피부 질환을 치료하기 위해 항-vegf 화합물을 도포하고 이러한 화합물을 이용하기 위한 시스템, 장치, 및 방법
CN112526037A (zh) * 2020-12-07 2021-03-19 温州市质量技术检测科学研究院 一种检测巴克球中苦精的方法
CN114668748A (zh) * 2022-05-18 2022-06-28 张钊源 渐变型透皮贴剂及其制备方法、药物方面的应用
WO2024189206A1 (en) * 2023-03-15 2024-09-19 Lts Lohmann Therapie-Systeme Ag Hexagonal self-adhesive layer structure

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
AU9147691A (en) * 1990-11-28 1992-06-25 Sano Corporation Method and device for treating tobacco addiction
KR19990026792A (ko) * 1997-09-26 1999-04-15 김윤 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제
US6312716B1 (en) * 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
AR039336A1 (es) * 2002-04-23 2005-02-16 Alza Corp Sistemas analgesicos transdermicos con potencial de abuso reducido
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
EP1615712B1 (en) * 2003-04-04 2012-03-28 Board Of Regents, The University Of Texas System Polyamine/alkali salt blends for carbon dioxide removal from gas streams
CN1780611B (zh) * 2003-04-30 2013-01-30 珀杜医药公司 包括活性剂部分以及在活性剂层远侧的逆转剂的抗改造透皮剂型
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
KR20060120678A (ko) * 2003-10-30 2006-11-27 알자 코포레이션 남용될 가능성이 감소된 경피용 진통제 시스템
HUE030128T2 (en) * 2004-02-23 2017-04-28 Euro Celtique Sa Anti-abuse device for transdermal opioid administration
JP5213204B2 (ja) * 2004-03-08 2013-06-19 リンテック株式会社 粘着シートおよびその製造方法
KR100663163B1 (ko) * 2005-10-24 2007-01-02 (주)아모레퍼시픽 비스테로이드성 소염진통제를 함유하는 경피 투여 제제
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008133982A2 (en) * 2007-04-27 2008-11-06 Lectec Corporation Adhesive patch with aversive agent
NZ589542A (en) * 2008-05-30 2012-10-26 Mylan Inc Transdermal drug delivery system comprising an active agent in amorphous form and polyvinylpyrrolidone
CN102782069B (zh) * 2009-04-27 2014-03-19 艾利丹尼森公司 用于根据需要运送和脱粘的系统、方法和材料
WO2011085406A1 (en) * 2010-01-11 2011-07-14 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
US20110293681A1 (en) * 2010-02-26 2011-12-01 Lectec Corporation Hand sanitizing patch having an integrally bonded antimicrobial
JP2013523780A (ja) * 2010-04-02 2013-06-17 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤
DK3096746T3 (da) * 2014-01-22 2019-05-20 4P Therapeutics Transdermale systemer til forhindring af misbrug eller forhindring af fejlanvendelse
CN112741822A (zh) * 2019-10-30 2021-05-04 江苏集萃新型药物制剂技术研究所有限公司 一种用于皮肤或粘膜释放活性物质的透皮贴剂给药系统

Also Published As

Publication number Publication date
US20240000720A1 (en) 2024-01-04
AU2015209466A1 (en) 2016-08-11
CA2937649C (en) 2022-11-01
JP2017505312A (ja) 2017-02-16
JP6525165B2 (ja) 2019-06-05
EP3096746A4 (en) 2017-08-23
WO2015112563A2 (en) 2015-07-30
RU2016133853A3 (es) 2018-09-18
LT3096746T (lt) 2019-06-10
EP3096746B1 (en) 2019-03-13
US11759431B2 (en) 2023-09-19
SI3096746T1 (sl) 2019-07-31
CN115475048A (zh) 2022-12-16
MX2016009493A (es) 2017-05-09
EP3096746A2 (en) 2016-11-30
RU2700926C2 (ru) 2019-09-24
KR102226652B1 (ko) 2021-03-12
CA2937649A1 (en) 2015-07-30
RS58759B1 (sr) 2019-06-28
PL3096746T3 (pl) 2019-09-30
US11246840B2 (en) 2022-02-15
CN106459293A (zh) 2017-02-22
US20220125739A1 (en) 2022-04-28
US20200113845A1 (en) 2020-04-16
CY1121654T1 (el) 2020-07-31
US20190076374A1 (en) 2019-03-14
KR20160108831A (ko) 2016-09-20
HRP20191048T1 (hr) 2019-09-06
CN115444659A (zh) 2022-12-09
HUE044966T2 (hu) 2019-11-28
RU2016133853A (ru) 2018-03-02
AU2015209466B2 (en) 2019-03-07
DK3096746T3 (da) 2019-05-20
US20170007550A1 (en) 2017-01-12
PT3096746T (pt) 2019-06-17
WO2015112563A3 (en) 2015-11-19
ES2729871T3 (es) 2019-11-06
CN115475048B (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
MX369030B (es) Sistemas transdérmicos restrictivos de abuso y mal uso.
TN2015000493A1 (en) Transdermal delivery system
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
NZ704011A (en) Abuse deterrent pharmaceutical compositions for controlled release
MX2015000114A (es) Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada.
AR095441A1 (es) Formulaciones farmacéuticas resistentes a la adulteración, proceso de preparación, método
PH12015501169A1 (en) Transdermal delivery system
NZ627368A (en) Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
JP2014218522A5 (es)
GB201111485D0 (en) Drug composition and its use in therapy
MX366230B (es) Composiciones multipolimericas para liberación transdermica de farmaco.
MX2016011744A (es) Soluciones de buprenorfina de liberacion sostenida.
PH12015502280A1 (en) Transdermal delivery system comprising donepezil or its salt
MX2018015607A (es) Microestructura de acido hialuronico que tiene excelentes caracteristicas de solubilidad.
AR092820A1 (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MX2017003638A (es) Microparticulas inyectables para liberacion hiper-localizada de agentes terapeuticos.
NZ731309A (en) Buprenorphine dosing regimens
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
Balhara A curious case of the World Health Organization's (WHO) approach on alcohol use disorders--inferences from the WHO list of essential drugs
WO2013049026A3 (en) Neurabin scaffolding of the adenosine receptor and rgs4 regulates anti-seizure effect of endogenous adenosine
WO2014023869A3 (es) Aplicacion terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana
MX2018001320A (es) Sistema de administracion transdermica.
IN2014MU01185A (es)

Legal Events

Date Code Title Description
FG Grant or registration